This segment focuses on the research and development of novel peptide-based therapeutics for the treatment of obesity and related metabolic disorders, with a primary focus on pemvidutide. Research and development activities include preclinical studies, clinical trials (Phase 1b, Phase 2, and Phase 3), and formulation development. Technologies and methodologies include GLP-1/glucagon dual receptor agonists. The segment addresses the significant unmet medical need for effective and safe obesity treatments, aiming to improve patient outcomes by promoting weight loss and addressing metabolic complications. Market positioning is based on the potential of pemvidutide to offer superior efficacy and safety compared to existing treatments. Future opportunities include expanding the clinical development program, seeking regulatory approvals, and commercializing pemvidutide. Regulatory and clinical aspects involve interactions with the FDA and other regulatory bodies, as well as the design and execution of clinical trials. Partnerships and collaborations may be pursued to support manufacturing, commercialization, and further research.

This segment is dedicated to developing immunotherapeutic products for the treatment of liver diseases, particularly chronic hepatitis B (HepTcell). Research and development activities include preclinical studies, Phase 2 clinical trials, and manufacturing process development. The segment utilizes immunotherapeutic approaches to stimulate the immune system to clear the hepatitis B virus. The therapeutic area focuses on addressing the significant unmet medical need for a functional cure for chronic hepatitis B, aiming to improve patient outcomes by reducing liver damage and preventing disease progression. Market positioning is based on the potential of HepTcell to offer a novel treatment option for patients who have not responded to existing therapies. Future opportunities include expanding the clinical development program, seeking regulatory approvals, and commercializing HepTcell. Regulatory and clinical aspects involve interactions with regulatory bodies and the design and execution of clinical trials. Partnerships and collaborations may be pursued to support manufacturing, commercialization, and further research.